Medicinal Cannabis Matters – Weekly round-up 29th March 2024
Medicinal Cannabis Matters – Our weekly round-up of what has been happening in the world of medicinal cannabis this week.
This week, we discuss how CBD has the potential to manage symptoms of an Alcohol use disorder, how Limonene can reduce THC-induced anxiety, how patients using a medicinal cannabis treatment have reported benefits of a lasting quality of life, and how in Ireland medicinal cannabis has been approved for 53 treatments and the number is likely to go up. CBD Has Potential To Manage Symptoms Of Alcohol Use Disorder, New Scientific Review Finds.
CBD Has Potential To Manage Symptoms Of Alcohol Use Disorder, New Scientific Review Finds.
Read about how CBD has the potential to help manage symptoms of Alcohol use disorder by modulating brain networks that perpetuate addiction. And how the findings add further weight to the idea that cannabinoids such as CBD might be useful in treating substance use disorders.
Analysis – Limonene Terpene reduces THC-induced Anxiety.
The co-administration of THC and the terpene D-limonene is associated with reduced feelings of anxiety, according to data published in the journal Drug and Alcohol Dependence. Read the article below to find out more.
Medical Marijuana Patients Report Lasting Quality Of Life Benefits
According to recent studies medicinal cannabis patients have reported a sustained improvement in quality of life. The patients who took part in this study had been recommended medicinal cannabis by their doctor. Results show that many patients found improvement in physical and social functioning.
Medicinal cannabis has been approved for 53 patients with a number of conditions it can treat likely to increase.
In a parliamentary response to Independent TD Violet-Anne Wynne, Health Minister Stephen Donnelly said the purpose of the programme was to enable compassionate access to cannabis for medical reasons, where conventional treatment has failed. The report recommended that cannabis should be made available for the treatment only of patients with specified medical conditions who had failed to respond to all other previous treatments.
Disclaimer: This blog post and the following featured articles are for information only and any articles on external platforms may be amended at any time. Articles that we refer to in our weekly roundup do not reflect the views of Medicann.
